Lesional histopathological features in pityriasis rosea (PR) are non-specific (1). Our aim here is to investigate whether a histopathological take-off sign (TOS) is associated with PR. We searched our records, and retrieved the 30 most recent patients with PR diagnosed according to a diagnostic criteria (2). Eight records had histopathological images available. For each, we retrieved the next p...

1 Dr K Shilpa, MBBS,MD (DVL), Assistant Professor 2 Dr B Leelavathy, MBBS, MD(DVL), Professor and Head 3 Dr K Kavya, MD, Junior Resident 4 Dr DV Lakshmi, DVD, Junior Resident 5 Dr G Divya, MBBS,MD(DVL), Senior Resident Department of Dermatology, Venereology, Leprology, Bangalore Medical College and Research Institute, Bangalore. KR Market, Bengaluru-560002, Karnataka, India Corresponding author...

Pityriasis rosea (PR) is an acute, self-limited papulosquamous dermatosis localized on the trunk and extremities, that affects otherwise healthy adolescents and young adults. Although the classic presentation is readily recognized, atypical forms may present a challenge. Many atypical forms of the disease have been reported in the literature.[1]We report two cases with atypical features. Involv...

Sir, A 74-year-old female patient treated with angiotensin-converting enzyme inhibitor for arterial hypertension metformin and atorvastatin insulin-independent diabetes mellitus hyperlipidemia, respectively, consulted the outpatient dermatological clinic a rash that appeared fifteen days prior to consultation. The received second dose of mRNA COVID-19 vaccine on July 29, 2021, was due receive t...

Pityriasis rosea (PR) is an acute, self-limiting papulosquamous exanthem. A number of atypical variants of PR, regarding morphology and distribution of the lesions or severity of the symptoms, may be observed. Herein, we present the first case of atypical PR with hypopigmented lesions and a target-shape herald patch.

reported to be as high as 69%.[1] Common cutaneous adverse effects include maculopapular eruptions and erythematous eruptions. Toxic epidermal necrolysis, Stevens–Johnson syndrome and acute generalized exanthematous pustulosis have also been reported with the use of imatinib. Other reported cutaneous adverse effects include: hypopigmentation, lichenoid reactions, pityriasiform eruptions, purpur...